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Management of thyroid nodules in the era of precision medicine is continuously changing.
Neck ultrasound plays a pivotal role in the diagnosis and several ultrasound stratification
systems have been proposed in order to predict malignancy and help clinicians in
therapeutic and follow-up decision. Ultrasound elastosonography is another powerful
diagnostic technique and can be an added value to stratify the risk of malignancy of
thyroid nodules. Moreover, the development of new techniques in the era of “Deep
Learning,” has led to a creation of machine-learning algorithms based on ultrasound
examinations that showed similar accuracy to that obtained by expert radiologists.
Despite new technologies in thyroid imaging, diagnostic surgery in 50–70% of patients
with indeterminate cytology is still performed. Molecular tests can increase accuracy
in diagnosis when performed on “indeterminate” nodules. However, the more updated
tools that can be used to this purpose in order to “rule out” (Afirma GSC) or “rule
in” (Thyroseq v3) malignancy, have a main limitation: the high costs. In the last years
various image-guided procedures have been proposed as alternative and less invasive
approaches to surgery for symptomatic thyroid nodules. These minimally invasive
techniques (laser and radio-frequency ablation, high intensity focused ultrasound and
percutaneous microwave ablation) results in nodule shrinkage and improvement of local
symptoms, with a lower risk of complications and minor costs compared to surgery.
Finally, ultrasound-guided ablation therapy was introduced with promising results as
a feasible treatment for low-risk papillary thyroid microcarcinoma or cervical lymph
node metastases.
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INTRODUCTION
One of the main clinical challenge in endocrine clinical practice is certainly the management
of thyroid nodules disease. During the last years, new technologies have been developed and
new diagnostic and therapeutic approaches have been introduced to guide clinician through the
diagnosis, follow-up and therapeutic decision. This reviewwill provide an evidence-based summary
of the optimal approach to the management of thyroid nodules.
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THE KEY ROLE OF ULTRASOUND
The prevalence of nodular thyroid disease in the general
population is high, reaching 60% according to ultrasound and
autopsy findings (1–3), though the incidence of malignancy
is relatively low, ranging 1.6% and 12% (4, 5). Thyroid
ultrasonography (US) is the primary tool used for the diagnosis
and the initial cancer risk stratification of thyroid nodules.
Currently, it guides decision making for fine-needle aspiration
biopsy (FNA), the timing of subsequent clinical evaluations
during long-term follow-up (6), and the eligibility for active
surveillance of suspicious nodules (7). A complete report
should include a description of the whole thyroid parenchyma,
nodule location, size, and sonographic features, and assessment
of the lymph nodes in the neck (8–10). The US features
that should be evaluated for each nodule are: echogenicity,
composition (solid, cystic, mixed), margins, calcifications or
other hyperechoic foci, shape, and relations with the thyroid
capsule (11, 12). Ultrasound patterns associated with malignancy
include: hypoechogenicity, infiltrative, irregular, or lobulated
margins, micro-calcifications, taller-than-wide shape, absence
of a halo. However, none of these single US pattern have
sensitivity, specificity and accuracy high enough to be considered
predictive for malignancy (11, 13, 14). The combination of
US patterns leads to a higher specificity, but it associates to
a lower sensitivity (15). Finally, it is worth to mention that
the evaluation of these US features is characterized by a high
interobserver variability (16, 17). In the last decade, to improve
standardization of thyroid ultrasound reporting, the guidelines of
the American Association of Clinical Endocrinologists/American
College of Endocrinology/Associazione Medici Endocrinologi
(AACE/ACE/AME) (3), the 2015 guidelines of the American
Thyroid Association (ATA) (18), the guidelines of the European
Thyroid Association (ETA; EU-TIRADS, European Thyroid
Imaging Reporting and Data System) (8), the American College
of Radiology (ACR) TIRADS (9), and the Korean Society of
Thyroid Radiology’s K-TIRADS system, have proposed risk
stratification systems with the goal of detecting nodule at
greatest risk for malignancy and then to recommend graduated
size cut-offs for FNA cytology (19) (Table 1). All these risk-
stratification systems are similar, but there are some differences:
the endocrinological societies’ systems are based on recognition
of patterns, while ACR TIRADS is score-based, considering
5 US features and their sum to obtain the final classification
of the nodule. Furthermore, the weight of each sonographic
feature varies across various systems (e.g., echogenicity being
the most important one for EU-TIRADS, and composition
for K-TIRADS), and the size threshold to recommend FNA
is different, too. Some of the systems have been validated in
multicenter studies (20–22). Independent comparison studies
(usually involving 2–3 of the systems) were mostly retrospective
(23–28). Two prospective Italian studies compared the systems
developed by the British Thyroid Association, the ATA, and
the AACE/ACE/AME (29), or the ATA and the ETA (30)
and found no significant differences between overall diagnostic
accuracy. A recent study comparing the main five systems
endorsed by international societies, found that four of the five
(AACE/ACE/AME, ATA, ACR-, and EU-TIRADS) showed a
significant diagnostic value (31). The ACR TIRADS, which
classified over half of the requested biopsies as unnecessary, with
a negative predictive value of 97.8%, showed the best overall
performance (31). To reproduce these results in the real clinical
practice, an essential prerequisite is the adoption of a uniform
language and definition of suspicious features (10). Classification
of thyroid nodules using any of the five classification systems
results in higher interobserver agreement than evaluation of
single suspicious features, and identification of nodules needing
biopsy has an almost perfect agreement (32). However, a specific
“training by consensus” involving joint evaluation of images
can improve the reproducibility for all classifications (with
significant improvements for ATA, K-TIRADS, and EU-TIRADS
systems), even for trained clinicians with similar experience
(32). In recent years, the useful of ultrasound patterns to
stratify the risk of malignancy of indeterminate thyroid nodules,
has also been evaluated (33–35). Sonographic patterns were
associated with different rate of malignancy suggesting that
these systems are also able to stratify the risk of malignancy
in the subgroup of cytologically indeterminate thyroid. These
preliminary data suggest that sonographic patterns would be
useful not only to guide FNAC, but also to personalize
management after an indeterminate cytological results. Recently,
software applications performing automated image analysis
were also proposed to extract quantitative parameters using
a variety of mathematical methods. These approaches may
be the basis for computer-aided diagnosis (CAD) systems
to yield an automated “second opinion” (36). According to
some evidence, thyroid CADs based on artificial intelligence
may further improve diagnostic performance and reliability
(37). The use of thyroid CAD to differentiate malignant from
benign nodules showed accuracy similar to that obtained by
an expert radiologist (38, 39) and may reduce intra- and inter-
observer variability, that however, still remains (38). Ultrasound
elastography (USE) has emerged as an additional tool in
combination with B-Mode Ultrasound (US) for thyroid nodules
work-up. It is a non-invasive, cost-effective, dynamic diagnostic
method for the measurement of tissues elasticity (40, 41).
Malignant lesions tend to be harder and firmer than the
normal thyroid parenchyma or benign lesions, related to fibrosis
and higher expression of Galectin-3 and Fibronectin-1 (41–
43), suggesting that elastography can be useful to distinguish
between benign andmalignant thyroid nodule (43, 44). There are
two main elastography techniques to quantify thyroid nodules
stiffness currently in clinical use: strain elastography (SE),
which evaluates the degree of tissue deformation induced by
manual compression or acoustic forces, and in which tissue
deformation is parallel to the direction of the force; and
shear wave elastography (SWE), in which a push beam is
created and tissue displacement is perpendicular to the direction
of the force (45, 46). Many studies and meta-analyses have
identified for USE some limitations and confounding factors,
including nodule features (calcifications, cystic components,
size, position), the operator expertise, artifacts such as carotid
artery pulsation, coexistent systemic, or thyroid diseases
(Hashimoto’s thyroiditis, acromegaly, previous thermal ablation
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TABLE 1 | An overview of the standardized thyroid nodule US scoring systems proposed or endorsed by international practice guidelines.
Risk score AACE/AME/ACE ATA EU-TIRADS K-TIRADS
Suspicious
US features
• Marked hypoechogenicity
• Spiculated or lobulated
margins
• Microcalcifications
• Taller-than-wide shape
• Extrathyroidal growth
• Pathologic adenopathy
• Irregular margins (infiltrative,
microlobulated)
• Microcalcifications
• Taller-than-wide shape
• Rim calcifications with small
extrusive soft-tissue component
• Evidence of
extrathyroidal extension
• Non-oval shape
• Irregular margins
• Microcalcifications
• Marked hypoechogenicity
• Microcalcification
• Taller-than-wide shape
• Spiculated/
microlobulated margins
Category Low-risk:
Cysts (fluid component >80%)
Mostly cystic nodules with
reverberating artifacts and not
associated with suspicious US
signs
Isoechoic spongiform nodules,
either confluent or with regular
halo.
Risk of malignancy: 1%
FNA >20mm (selective)a
Benign:
Purely cystic nodules (no solid
component)
Risk of malignancy: <1%
FNA is not indicated
Benign (EU-TIRADS 2):
Pure/anechoic cysts; entirely
spongiform nodules
Risk of malignancy: ≈ 0%
FNA is not indicated
Benign:
Spongiform
Partially cystic nodule with
comet-tail artifact
Pure cyst
Risk of malignancy: <1–3
FNA ≥20 mm
Very low suspicion:
Spongiform or partially cystic nodules
without any of the US features
defining low-, intermediate,- or
high-suspicion patterns
Risk of malignancy: <3%
FNA ≥20mm or observation
Low-Risk (EU-TIRADS 3):
Oval shape, smooth margins,
isoechoic, or hyperechoic,
without any feature of high risk
Risk of malignancy: 2–4%
FNA >20 mm
Low suspicion:
Partially cystic or isohyperechoic
nodule without any of 3
suspicious
US features*
Risk of malignancy: 3–15%
FNA ≥15 mm
Low suspicion:
Isoechoic or hyperechoic solid
nodule, or partially cystic nodule with
eccentric solid area without:
microcalcifications, irregular margin,
extrathyroidal extension, taller than
wide shape
Risk of malignancy: 5–10%
FNA ≥15 mm
Intermediate-risk:
Slightly hypoechoic (vs. thyroid
tissue) or isoechoic nodules, with
ovoid-to-round shape, smooth
or ill-defined margins
May be present:
Intranodular vascularization
Elevated stiffness at
elastography,
Macro or continuous rim
calcifications
Indeterminate hyperechoic spots
Risk of malignancy: 5–15%
FNA: >20 mm
Intermediate suspicion:
Hypoechoic solid nodule with smooth
margins without: microcalcifications,
extrathyroidal extension or taller than
wide shape
Risk of malignancy: 10–20%
FNA ≥10 mm
Intermediate-Risk
(EU-TIRADS 4):
Oval shape, smooth margins,
mildly hypoechoic, without any
feature of high risk
Risk of malignancy: 6–17%
FNA >15 mm
Intermediate suspicion:
Solid hypoechoic nodule without
any suspicious US feature or
partially cystic or isohyperechoic
nodule with any of the following:
microcalcification, non-parallel
orientation (taller-than-wide),
spiculated/microlobulated
margin
Risk of malignancy: 15–50%
FNA ≥10 mm
(Continued)
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TABLE 1 | Continued
Risk score AACE/AME/ACE ATA EU-TIRADS K-TIRADS
High-risk:
Nodules with ≥1 of the following:
Marked hypoechogenicity (vs.
prethyroid muscles)
Spiculated or lobulated margins
Microcalcifications
Taller-than-wide shape (AP>TR)
Extrathyroidal growth
Pathologic adenopathy
Risk of malignancy: 50–90%b
FNA ≥10mm (5mm, selective)c
High suspicion:
Solid hypoechoic nodule or solid
hypoechoic component of partially
cystic nodule with ≥1 of the following:
Irregular margins (infiltrative,
microlobulated)
Microcalcifications
Taller than wide shape
Rim calcifications with small extrusive
soft tissue
Extrathyroidal extension
Risk of malignancy: >70–90%
FNA ≥10 mm
High-Risk (EU-TIRADS 5):
Nodules with ≥1 of the following:
Non-oval shape
Irregular margins
Microcalcifications
Marked hypoechogenicity
Risk of malignancy: 26–87%
FNA >10 mm
High suspicion:
Solid hypoechoic nodule with
any of the following:
Microcalcification
Nonparallel orientation
(taller-than-wide)
Spiculated/microlobulated
margin
Risk of malignancy: >60
FNA ≥10mm (>5mm selective)
aGrowing nodule, high-risk history, before surgery, or local therapies.
b In accordance with the presence of 1 or more suspicious findings.
cFNA is recommended for the following nodules: Subcapsular or paratracheal lesions; Suspicious lymph nodes or extrathyroid spread; Positive personal or family history of thyroid
cancer: History of head and neck irradiation, coexistent suspicious clinical findings (e.g., dysphonia).
or radiofrequency on thyroid nodule) and pathological type
of thyroid cancer (40, 41, 47–71). Therefore, USE should be
performed in selected thyroid nodules by qualified operators
using objective criteria provided by elastographic machines.
Two clinical practice guidelines include recommendation on
thyroid USE. The 2015 ATA guidelines (18) reported that
USE may be a helpful tool for preoperative risk assessment in
patients, although it cannot be universally recommended. The
2016 AACE/ACE/AME guidelines (3) reported that USE data
are complementary to gray-scale findings, especially in nodules
with indeterminate US or cytological findings. Moreover, other
specialized guidelines specific for USE [European Federation of
Societies for Ultrasound inMedicine and Biology (EFSUMB) (72)
and World Federation of Societies for Ultrasound in Medicine
and Biology (WFSUMB) guidelines (50)], provide an adequate
description of the technique and its reproducibility, results and
limitations. Although many reports have demonstrated that
USE performed the same or better than the gray-scale US (40,
41), its diagnostic efficacy is still controversial (73). In clinical
practice USE is usually performed as a complementary tool
to conventional US, as the combination of the two techniques
proved to have higher sensitivity (74). Recently, some studies
evaluated the potential role of elastography in non-diagnostic or
indeterminate nodules (43, 75), even if conventional US also has
been shown to display good diagnostic results (37, 76). Utility
of USE has also been explored in many studies (40, 54, 77, 78)
but therefore, other authors failed to demonstrate the diagnostic
utility in indeterminate nodules (75, 79) and a meta-analysis of
eight studies demonstrated there was a great variability of both
sensitivity and specificity in USE, with pooled estimates of 69 and
75%, respectively (77). Further studies are required concerning
the supplementary role of elastography in the risk stratification
of thyroid nodules.
HAVE MOLECULAR ANALYSIS AN ADDED
VALUE?
When thyroid nodules are evaluated with fine-needle aspiration
biopsy (FNAB), in ∼5–20% of cases it is not possible to
discriminate between benign and malignant nodules because of
an indeterminate cytology (78). According to The Bethesda
System for Reporting Thyroid Cytopathology (79, 80)
indeterminate cytology includes two different categories:
atypical or follicular lesion (Bethesda III) and follicular
neoplasm/suspicious for follicular (or Hürthle cell) neoplasm
(Bethesda IV). The observed rates of cancer in these categories
vary widely ranging from 6 to 48% for Bethesda III and 14
to 34% for Bethesda IV (81). This wide range of cancer risk,
involves that diagnostic hemithyroidectomies are still performed
in order to discriminate between benign and malignant nodules.
Unfortunately, in 50–70% of patients with indeterminate
cytology a diagnostic surgery is performed. Moreover, surgery
exposes patients to surgical risks and in the event of malignant
lesions, a second-stage surgery is often indicated with additional
costs and risks for patients (82–85). Molecular tests using gene
expression and/or mutational analysis, have been developed
to reduce the need for diagnostic surgery for indeterminate
(Bethesda III/IV) thyroid nodules (86). Several molecular tests
have been proposed over the years, since different gene-mutation
panels has been introduced (86), with reported NPV and PPV
ranging from 56 to 100% and from 19 to 100%, respectively,
and the most successful are the Thyroseq and the AFIRMA
Gene Expression Classifier (GEC). The first version of Thyroseq
included the 7 gene panel (BRAF, H-K-N-RAS, RET/PTC1-3,
PAX8/PPARγ) (87) with a reported sensitivity of about 65%
(87–89). Following versions migrated to the next generation
sequencing platforms (NGS) and included a 13-gene panel
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(ThyroSeq v1) (90) and a 56-gene panel (ThyroSeq v2) with a
significant increase in sensitivity and negative predictive value
(NPV) (91, 92). The last version of Thyroseq, v3, Nikiforov
and Baloch (92) is a targeted NGS test that evaluates point
mutations, gene fusions, copy number alterations and abnormal
gene expression in 112 thyroid cancer related genes. Using the
last version of Thyroseq, a recent prospective and multicenter
validation study (93) on 286 cytological indeterminate nodules
submitted to surgery reported a 94% of sensitivity and 82% of
specificity with a NPV of 97% and a positive predictive value
(PPV) of 66%. These data may obviate diagnostic surgery in up to
61% of patients with indeterminate nodules. The AFIRMA GEC
is a microarray based test with a proprietary algorithm able to
differentiate benign frommalignant nodules based on messenger
RNA expression pattern. The sensitivity is approximately of
90%, but the specificity is lower (88, 94). Moreover, a significant
site to site variability in the benign call rate (range 27–53%)
and in the malignancy rate (range 15.6–70%) was reported in
a follow-up multicenter study (95).Very recently, the AFIRMA
Genomic Sequencing Classifier (GSC) replaced the original
GEC. It is a RNA sequencing based test, including 12 classifiers
composed of 10,196 genes and 7 additional components in
order to exclude parathyroid lesions and medullary thyroid
cancer, and includes the analysis of BRAFV600E mutations,
RET/PTC1 or RET/PTC3 and of specific alterations typical of
Hurtle cell lesions. Compared to GEC, the GSC has a better
specificity and reduces the number of histological benign samples
classified as suspicious. An initial validation study showed a 36%
increase in specificity compared with the GEC with a reported
sensitivity of about 91% (96). Harrell et al. (97) demonstrated
that GSC is able to identify less indeterminate cytology nodules
as suspicious when compared to GEC, suggesting that GSC
further reduces surgery by improving in specificity. In a recent
independent study, Endo et al. (98) compared GEC with GSC
and demonstrated that GSC had a significant higher benign
call rate (76.2 vs. 48.1%), PPV (60.0 vs. 33.3%), and specificity
(94.3 vs. 61.4%) than GEC in both Bethesda III and Bethesda IV
categories. In particular, benign call rate of GSC was significantly
higher in nodules with Hürthle cell changes (88.8 vs. 25.7%).
In summary, both ThyroSeq and AFIRMA have reached a high
sensitivity and enough specificity to function as rule in and rule
out tests. The main problem is the limited number of validation
studies and the high costs that remain a limit in their worldwide
utilization. Currently, there are no data to prefer a molecular
test rather than another one, and long term outcome data
are needed.
MINI INVASIVE TREATMENTS
Most benign thyroid nodules are asymptomatic, stable and do
not require treatment, while large thyroid nodules may become
responsible for pressure symptom, neck discomfort or cosmetic
complaints thus resulting in decreased quality of life (99).
Over the last two decades, non-surgical, minimally invasive US-
guided techniques have been proposed for the treatment of
symptomatic nodules. Minimally invasive procedures include
percutaneous ethanol injection (PEI), laser thermal ablation
(LTA), radiofrequency ablation (RFA), high intensity focused
ultrasound (HIFU), and percutaneous microwave ablation
(PMWA) (Table 2). PEI represents the first-line treatment
for thyroid cysts and nodules with a predominant fluid
component (100), while in solid nodules, LTA and RFA have
proven to be very effective and safe in producing significant
and stable reduction of nodule volume (101). Radiofrequency
thermoablation consists in thermal ablation of the nodular
tissue by exploiting the heat released by an energy source with
consequent coagulation necrosis. The purpose of the treatment
is to determine a volumetric reduction of the thyroid nodule,
a condition that usually occurs in the weeks and months
following the procedure as a consequence of the gradual
replacement of the thyroid tissue with fibro-scar tissue and
the procedure can be repeated after some time (102). Overall
complication rate is low, about 3.5% (103). Some authors
reported an higher difficulty of surgery after treatments, and
exists the rare possibility of cancer spreading while treating
patients with supposedly benign nodules (104). Radiofrequency
thermoablation can be used for the treatment of benign nodular
masses on cytological evaluation, which cause aesthetic alteration
or compressive symptoms which cannot be treated surgically,
for comorbidities or patient’s preference. It is also recommended
for the treatment of both pre-toxic and toxic nodules, when
surgery or radioiodine are contraindicated or refused by the
patient (3, 102, 105). Radiofrequency thermoablation has been
proposed for papillary thyroid microcarcinoma and in cases of
recurrence or loco-regional persistence of thyroid carcinoma
when surgery is contraindicated or radiometabolic therapy has
proved ineffective (18, 106). Some limitations still remain, such
as the difficult to determine if cancer cells are fully eliminated
even if ablation zones completely disappear on US and long-
term outcomes (107). Another procedure based on the principles
of hyperthermia is LTA that significantly reduce thyroid nodule
volume as well as symptoms and cosmetic problems, due to
coagulative necrosis into the target tissue (108, 109). A 3-
year multicenter prospective randomized trial with LTA showed
persistent volume reduction and local symptom improvement
at 36 months after treatment (110). A systematic meta-analysis,
comparing the efficacy of RFA and LTA for the treatment of
benign thyroid nodules, concluded that both LTA and RFA are
able to significantly decrease nodule volume, though RFA has
a superior efficacy to LTA in nodule shrinkage despite minor
number of treatment sessions (111). Only one study reported
minor complications, as transient thyrotoxicosis and fever, after
LTA (112) while no studies reported major complications such
as voice change or hypothyroidism after either RFA or LA. It
remains unclear if the different results are linked to the different
energy delivered per ml of thyroid tissue, to the treatment time
or technique. Finally, HIFU and PMWA are other promising
forms of thermal ablation technique, but need further clinical
testing. High intensity focused ultrasound (HIFU) have some
advantages over other ablation techniques such as the ability
to induce a focused thermal tissue destruction without needle
puncture and seems to be less dependent on the skill of the
operator. However, it produces thermal coagulation within a
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TABLE 2 | An overview of the non-surgical, Image-Guided, Minimally Invasive Therapy for thyroid nodules or recurrent thyroid cancer.
Clinical Indication Treatment
First line Second Line
Cysts or predominantly cystic
benign thyroid nodules
• Cystic nodules (>90% of fluid
composition)
• Predominantly cystic nodules
(51–90% of fluid component)
• Us-guided percutaneous ethanol
ablation (PEI)
• Us-guided thermal ablation
RFA can be recommended as the next step
in cases with incomplete resolved symptoms
due to the residual solid component or
recurrence following PEI
Solid non-functioning (cold)
benign thyroid nodules
• Benign, non-functioning solid
nodules with symptoms or
cosmetic problems
• Benign, non-functioning solid
nodules that progressively enlarge
• Benign multinodular goiter in
patient who refuse or cannot
undergo surgery
• Thermal ablation (Radiofrequency
ablation, laser ablation)
• Surgery
Autonomously functioning
thyroid nodules (AFTN)
• Radioactive iodine (RAI)
• Surgery
• Thermal ablation (Radiofrequency ablation,
laser ablation)
Primary Thyroid Cancer Follicular
neoplasm
• Surgery • Thermal ablation
Who refuse surgery or who cannot undergo
an operation, thermal ablations can be
considered as an alternative. Radiofrequency
ablation, laser ablation, and microwave
ablation have been attempted for patients
with papillary thyroid
microcarcinoma (PTMC).
DTC patients with metastatic
disease
• Surgery
• TSH-suppressive thyroid hormone
therapy for patients with stable or
slowly progressive asymptomatic
disease
• 131-I therapy for
RAI-responsive disease
• External beam radiation therapy
• Thermal ablation
• Systemic therapy with kinase inhibitors
small volume and the ablation of a larger tissue volume may
take an excessive period of time (113). The treatment efficacy
(i.e., extent of nodule shrinkage at 6-month) in larger-sized
benign thyroid nodules has been evaluated by Lang et al.
in 63 nodules with a noticeably less efficacy for larger-sized
nodules (114). HIFU is a safe treatment although transient
side effects have been reported, such as pain, skin redness,
mild subcutaneous swelling and transient vocal cord paralysis
(115, 116). Percutaneous microwave ablation (PMWA) is a new
technique that produce a rapid increase of the target tissue
temperature through the rotation of molecules produced from
microwave energy. Few studies analyzed the effectiveness of
PMWA in the treatment of benign solid thyroid nodules. Liu
et al. evaluated 474 benign thyroid nodules in 435 patients
treated with PMWA showing a mean 90% decrease in volume
at 1-year, with no major complications described (70). Another
study by Yue et al. reported, in 110 patients treated with
PMWA, a significant reduction at 1 year (ranging from 12.6
± 15.1 to 3.2 ± 5.7mL) (117). A retrospective, observational
trial at a single institution compared the efficacy and safety of
RFA in 40 patients, PMWA in 40 patients and HIFU in 14
patients with small nodules at 3 months after ablation. RFA
showed a slightly better mean volume reduction of nodules
(50%) than MWA (44%) and HIFU (48%). The study limitation
is the short period of time (118). In conclusion, non-surgical
minimally invasive approaches can be used to treat symptomatic
or enlarging thyroid nodule and appear safe and effective.
Currently, percutaneous ethanol injection (PEI) is recommended
for symptomatic cystic or relapsing cystic lesions. Either laser
thermal ablation (LTA) or radiofrequency ablation (RFA) can
be used for symptomatic solid nodules. Microwave ablation
(PMWA) or high intensity focused ultrasound (HIFU) are
newer techniques with promising results that await further
clinical evaluation.
DISCUSSION
In the era of precision medicine, the most important
landmark remains the correct identification of malignant
thyroid nodules. Newer and promising imaging techniques
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combined with the more accurate molecular examination will
be able to reduce diagnostic uncertainty. Moreover, newer
therapeutic options will be able to reduce, when possible,
avoidable thyroidectomy. These approaches will allow the
clinician to set up a tailored management, from diagnosis
to treatment, of thyroid nodule disease, according to the
patient’s needs.
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